NP	Eustonger No. 28880	•	Confirmation No. 9185
HAPE O	3 2000		PTO/SB/21 (03-03) Approved for use through 04/30/2003. OMB 0651-0031 Int and Trademark Office; U.S. DEPARTMENT OF COMMERCE ion of information unless it displays a valid OMB control number.
	AT	Application Number	10/602,414
SHAFIT & TO	TRANSMITTAL	Filing Date	June 23, 2003
	FORM	First Named Inventor	David James Dooley, et al.
•	(to be used for all correspondence after initial filing)	Art Unit	1614 -
		Examiner Name	Unknown
t	Total Number of Pages in This Submission	Attorney Docket Number	PC25218A

		ENCLOSURES (Check all that appl	y)
	Fee Transmittal Form	Drawing(s)	After Allowance Communication to a Technology Center (TC)
	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s)	Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address Terminal Disclaimer Request for Refund CD, Number of CD(s) Remarks AUTHORIZATION TO CHARGE THE FNECESSARY OR CREDIT ANY OVERS	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Statement as Provided by 37 CFR 1.97(b) Return Post Card
	Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	23-0455 IS HEREBY GIVEN.	
	OLONIA	THE OF ARRIVANT ATTORNEY	OD ACENT
<u></u>		TURE OF APPLICANT, ATTORNEY,	JR AGENT
Firm or Individ	David R. Kurlandsky		
Signa	7 7 7		
Date	7250		
	C	ERTIFICATE OF TRANSMISSION/MA	ILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United State first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450 on this date

Linda A. Zerby

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Typed or printed

Signature

: Method of Treating Deficit Hyperactivity Disorder

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

Dear Sir:

FOR

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (MPEP § 1302.12).

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Datad:

Respectfully submitted,

David R. Kurlandsky Registration No. 41,505

Warner-Lambert Company

2800 Plymouth Road Ann Arbor, MI 48105

Telephone: (734) 622-7304

Facsimile: (734) 622-1553

Sheet

& TRAD

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ler the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Cor	Complete if Known				
Application Number	10/602,414				
Filing Date	June 23, 2003				
First Named Inventor	David James Dooley, et al.				
Art Unit	1614				
Examiner Name	Unknown				
Attorney Docket Number	PC25218A				

F	T 04-	5	Dublication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		^{US-} 4024175	05-17-1977	Gerhard Satzinger, et al.	
		^{US-} 4087544	05-02-1978	Gerhard Satzinger, et al.	
		US- 5563175	10-08-1996	Richard B. Sliverman, et al.	
		US-6316638	11-13-2001	Justin S. Bryans, et al.	
		US- 642084	10-80-2002	Stephen L. Dewey, et al.	
		US-			
		US-			
		US-			
		US-			
		US-		10.110	
		US-			

		FORE	IGN PATENT DOC	UMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	١.
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Τ,
		WO 98/17627	04-30-1998	Justin S. Bryans, et al.		
		WO 99/08671	02-25-1999	Antonio Guglietta, et al.		
		WO 99/31057	06-24-1999	Justin S. Bryans, et al.		
		WO 99/31074	06-24-1999	Thomas R. Belliotti, et al.		
		WO 99/31075	06-24-1999	Justin S. Bryans, et al.		
		WO 99/61424	12-02-1999	Justin S. Bryans, et al.		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known			
Cubsilities for form 1443/1/10	Application Number	10/602,414		
INFORMATION DISCLOSURE	Filing Date	June 23, 2003		
	First Named Inventor	David James Dooley, et al.		
STATEMENT BY APPLICANT	Art Unit	1614		
(Use as many sheets as necessary)	Examiner Name	Unknown		

Attorney Docket Number | PC25218A

F	0:4-	Danis and March an	U. S. PATENT D	Name of Detector or	Bagge Columns Lines Where
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}			Figures Appear
		US-		•	\
		US-			
		US-			•
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			
		US-			
- **		US-			
		US-	 		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 *} Number ^{4 *} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO 00/15611	03-23-2000	Justin S. Bryans, et al.		
		WO 01/28978	04-26-2001	Justin S. Bryans, et al.		
						L
				,		-
						L

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here If English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE Application Number 10/602,414 Filing Date June 23, 2003	Complete if Known	
Substitute for form 1449/17 TO	Application Number	10/602,414
INFORMATION DISCLOSURE	Filing Date	June 23, 2003
STATEMENT BY APPLICANT	First Named Inventor	David James Dooley, et al.
(Use as many sheets as necessary)	Art Unit	1614
(USE as many sneets as necessary)	Examiner Name	Unknown
Sheet 3 of 3	Attorney Docket Number	PC25218A

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		D. J. DOOLEY, et al., "Stimulus-Dependent Modulation of [3H]Norepinephrine Release from Rat Neocortical Slices by Gabapentin and Pregabalin", The Journal fo Pharmacology and Expermental Therapeutics, 2000, pp 1086-1093, Vol. 295, No. 3	
		K. FINK, et al., "Inhibition of Neuronal Ca2+influx by Gabapentin and Pregabalin in the Human Neocortex", Neuro Pharmacology, 2002, pp 229-236, Vol. 42	
		V. HAMRIN, et al., "Gabapenting and Methylphenidate Treatment of a Preadolescent with Attention Deficity Hyperactivity Disorder and Bipolar Disorder", Journal of Child and Adolescent Psychopharmacology, 2002, pp 301-309, Vol. 11, No. 3	
		H. V. KASATOKOVA, et al., "Research of Catecholamine Metabolism Peculiarities of the Children with Attention Deficit Hyperactivity Disorder", Database Biosis Online, Database Accession No. PREV200100125251 ABSTRACT ONLY	
		R. RYBACK, et al., "Gabapentin for Behavioral Dyscontrol", American Journal of Psychiatry September 1995, pp 1399, Vol. 152, No. 9	
-			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: